menu search

MGTA / Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities. Read More
Posted: Dec 21 2022, 09:02
Author Name: Zacks Investment Research
Views: 102136

MGTA News  

MGTA Stock: 51.66% Surge Explained

By Pulse2
February 5, 2023

MGTA Stock: 51.66% Surge Explained

The stock price of Magenta Therapeutics Inc (NASDAQ: MGTA) surged by 51.66% in the most recent trading session. This is why. more_horizontal

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

By Zacks Investment Research
December 21, 2022

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limitin more_horizontal

Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%

By Pulse2
December 20, 2022

Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%

The stock price of Magenta Therapeutics (MGTA) plummeted over 50% intraday today. This is why. more_horizontal

After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

By Zacks Investment Research
May 16, 2022

After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to t more_horizontal


Search within

Pages Search Results: